

December 8, 2021

Pharmacy and Therapeutics Committee  
State of Nevada Department of Health and Human Services  
Division of Health Care Financing and Policy  
1100 E. Williams Street, Suite 101  
Carson City, Nevada 89701

To Whom It May Concern,

I am writing this letter in support of the potential for adding Caplyta to your formulary. I have had many recent experiences with respect to prescribing Caplyta for my schizophrenic patients. I have been impressed with its efficacy and I have equally found that its metabolic side effect profile has been especially helpful for patients who would otherwise potentially gain weight or have lipid related issues or a propensity towards diabetes and/or other comorbid medical problems. I appreciate the fact that its once a day dosing and no titration requirements, makes it easy to use both for practitioners and patients alike. Ease of use with patients is especially important, given that compliance or adherence issues are especially problematic with patients who have this disease state. Furthermore, given the heterogenicity of schizophrenia, the more psychotropic medications that are available to address this severe, debilitating and significant mental health related disease, the potential for better treatment outcomes is possible. Please give thought to adding it to the formulary.

If further information is requested, please do not hesitate to contact me.  
Sincerely,

David E. Linden, M.D.